AAV-mediated editing of PMP22 rescues Charcot-Marie-Tooth disease type 1A features in patient-derived iPS Schwann cells.
Journal
Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
received:
21
03
2023
accepted:
03
11
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
28
11
2023
Statut:
epublish
Résumé
Charcot-Marie-Tooth disease type 1A (CMT1A) is one of the most common hereditary peripheral neuropathies caused by duplication of 1.5 Mb genome region including PMP22 gene. We aimed to correct the duplication in human CMT1A patient-derived iPS cells (CMT1A-iPSCs) by genome editing and intended to analyze the effect on Schwann cells differentiated from CMT1A-iPSCs. We designed multiple gRNAs targeting a unique sequence present at two sites that sandwich only a single copy of duplicated peripheral myelin protein 22 (PMP22) genes, and selected one of them (gRNA3) from screening their efficiencies by T7E1 mismatch detection assay. AAV2-hSaCas9-gRNAedit was generated by subcloning gRNA3 into pX601-AAV-CMV plasmid, and the genome editing AAV vector was infected to CMT1A-iPSCs or CMT1A-iPSC-derived Schwann cell precursors. The effect of the genome editing AAV vector on myelination was evaluated by co-immunostaining of myelin basic protein (MBP), a marker of mature myelin, and microtubule-associated protein 2(MAP2), a marker of neurites or by electron microscopy. Here we show that infection of CMT1A-iPS cells (iPSCs) with AAV2-hSaCas9-gRNAedit expressing both hSaCas9 and gRNA targeting the tandem repeat sequence decreased PMP22 gene duplication by 20-40%. Infection of CMT1A-iPSC-derived Schwann cell precursors with AAV2-hSaCas9-gRNAedit normalized PMP22 mRNA and PMP22 protein expression levels, and also ameliorated increased apoptosis and impaired myelination in CMT1A-iPSC-derived Schwann cells. In vivo transfer of AAV2-hSaCas9-gRNAedit to peripheral nerves could be a potential therapeutic modality for CMT1A patient after careful examinations of toxicity including off-target mutations. Charcot-Marie-Tooth disease type 1A (CMT1A) is a common heritable form of the condition that develops when nerves in the body’s extremities, such as the hands, feet and arms, are damaged due to an extra copy of PMP22 gene being incorrectly produced. Currently, no known therapies exist. Here, we developed a method to delete the additional copy of PMP22 gene by 20–40% to prevent overproduction. Our results show that this method can reduce PMP22 protein production, leading to near normal production in patient’s nerve cells. Further safety assessments should now be undertaken. If the treatment is safe for patients it could become a therapeutic option for CMT1A patients.
Sections du résumé
BACKGROUND
BACKGROUND
Charcot-Marie-Tooth disease type 1A (CMT1A) is one of the most common hereditary peripheral neuropathies caused by duplication of 1.5 Mb genome region including PMP22 gene. We aimed to correct the duplication in human CMT1A patient-derived iPS cells (CMT1A-iPSCs) by genome editing and intended to analyze the effect on Schwann cells differentiated from CMT1A-iPSCs.
METHODS
METHODS
We designed multiple gRNAs targeting a unique sequence present at two sites that sandwich only a single copy of duplicated peripheral myelin protein 22 (PMP22) genes, and selected one of them (gRNA3) from screening their efficiencies by T7E1 mismatch detection assay. AAV2-hSaCas9-gRNAedit was generated by subcloning gRNA3 into pX601-AAV-CMV plasmid, and the genome editing AAV vector was infected to CMT1A-iPSCs or CMT1A-iPSC-derived Schwann cell precursors. The effect of the genome editing AAV vector on myelination was evaluated by co-immunostaining of myelin basic protein (MBP), a marker of mature myelin, and microtubule-associated protein 2(MAP2), a marker of neurites or by electron microscopy.
RESULTS
RESULTS
Here we show that infection of CMT1A-iPS cells (iPSCs) with AAV2-hSaCas9-gRNAedit expressing both hSaCas9 and gRNA targeting the tandem repeat sequence decreased PMP22 gene duplication by 20-40%. Infection of CMT1A-iPSC-derived Schwann cell precursors with AAV2-hSaCas9-gRNAedit normalized PMP22 mRNA and PMP22 protein expression levels, and also ameliorated increased apoptosis and impaired myelination in CMT1A-iPSC-derived Schwann cells.
CONCLUSIONS
CONCLUSIONS
In vivo transfer of AAV2-hSaCas9-gRNAedit to peripheral nerves could be a potential therapeutic modality for CMT1A patient after careful examinations of toxicity including off-target mutations.
Charcot-Marie-Tooth disease type 1A (CMT1A) is a common heritable form of the condition that develops when nerves in the body’s extremities, such as the hands, feet and arms, are damaged due to an extra copy of PMP22 gene being incorrectly produced. Currently, no known therapies exist. Here, we developed a method to delete the additional copy of PMP22 gene by 20–40% to prevent overproduction. Our results show that this method can reduce PMP22 protein production, leading to near normal production in patient’s nerve cells. Further safety assessments should now be undertaken. If the treatment is safe for patients it could become a therapeutic option for CMT1A patients.
Autres résumés
Type: plain-language-summary
(eng)
Charcot-Marie-Tooth disease type 1A (CMT1A) is a common heritable form of the condition that develops when nerves in the body’s extremities, such as the hands, feet and arms, are damaged due to an extra copy of PMP22 gene being incorrectly produced. Currently, no known therapies exist. Here, we developed a method to delete the additional copy of PMP22 gene by 20–40% to prevent overproduction. Our results show that this method can reduce PMP22 protein production, leading to near normal production in patient’s nerve cells. Further safety assessments should now be undertaken. If the treatment is safe for patients it could become a therapeutic option for CMT1A patients.
Identifiants
pubmed: 38017287
doi: 10.1038/s43856-023-00400-y
pii: 10.1038/s43856-023-00400-y
pmc: PMC10684506
doi:
Types de publication
Journal Article
Langues
eng
Pagination
170Subventions
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 16H02655, 19H01042, 22H00464
Organisme : Ministry of Education, Culture, Sports, Science and Technology (MEXT)
ID : 22110001, 22110002
Informations de copyright
© 2023. The Author(s).
Références
Stem Cell Reports. 2017 Jun 6;8(6):1714-1726
pubmed: 28506533
Genes Dev. 1995 Aug 1;9(15):1846-56
pubmed: 7649472
Sci Rep. 2019 Jan 24;9(1):642
pubmed: 30679613
Ann Neurol. 2011 Jan;69(1):22-33
pubmed: 21280073
Biochemistry. 2010 Apr 27;49(16):3456-63
pubmed: 20334434
Lancet Neurol. 2011 Apr;10(4):320-8
pubmed: 21393063
Commun Biol. 2021 Mar 9;4(1):317
pubmed: 33750896
Nat Med. 2014 Sep;20(9):1055-61
pubmed: 25150498
Hum Mol Genet. 1993 Dec;2(12):2031-5
pubmed: 8111370
Muscle Nerve. 2013 Oct;48(4):604-22
pubmed: 23801417
J Peripher Nerv Syst. 2023 Jun;28(2):134-149
pubmed: 36855793
Nat Genet. 1992 Dec;2(4):292-300
pubmed: 1303282
Nucleic Acids Res. 2014 Dec 16;42(22):e168
pubmed: 25300484
Orphanet J Rare Dis. 2014 Mar 19;9:38
pubmed: 24646194
J Biol Chem. 2009 Aug 21;284(34):23146-58
pubmed: 19546221
BMC Genomics. 2016 Nov 28;17(1):979
pubmed: 27894274
Sci Adv. 2017 Jul 05;3(7):e1700220
pubmed: 28695207
Nat Genet. 1992 Jun;1(3):166-70
pubmed: 1303229
Mol Psychiatry. 2018 Oct;23(10):2090-2110
pubmed: 30283027
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Microsc Res Tech. 1998 Jun 1;41(5):359-71
pubmed: 9672419
Bioinformatics. 2014 May 15;30(10):1473-5
pubmed: 24463181
Nat Commun. 2021 Apr 21;12(1):2356
pubmed: 33883545
Hum Mol Genet. 2001 May 1;10(10):1007-18
pubmed: 11331611
Ann Hum Genet. 2008 May;72(Pt 3):416-41
pubmed: 18215208
J Biol Chem. 2021 Jan-Jun;296:100719
pubmed: 33933451
Biochim Biophys Acta Biomembr. 2020 Jun 1;1862(6):183256
pubmed: 32145283
Mol Biol Cell. 2000 Sep;11(9):2901-14
pubmed: 10982389
Cold Spring Harb Perspect Biol. 2015 Jun 08;7(8):a020529
pubmed: 26054742
Mol Ther. 2014 Mar;22(3):511-521
pubmed: 24162799
Int J Mol Sci. 2021 Jun 03;22(11):
pubmed: 34205075
Nat Med. 2014 Sep;20(9):984-5
pubmed: 25198045
Neural Regen Res. 2023 Jul;18(7):1434-1440
pubmed: 36571339
J Neurosci. 1996 Sep 1;16(17):5351-60
pubmed: 8757248
Neurobiol Dis. 2017 Apr;100:99-107
pubmed: 28108290
Mol Neurobiol. 2013 Apr;47(2):673-98
pubmed: 23224996
Cells. 2020 Jul 02;9(7):
pubmed: 32630835
Mol Biotechnol. 2023 Nov;65(11):1729-1736
pubmed: 36881252
Glia. 1998 Jun;23(2):89-98
pubmed: 9600378
Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):483-8
pubmed: 11752407
Neuron. 1996 May;16(5):1049-60
pubmed: 8630243
Neurology. 2022 May 11;:
pubmed: 35545446
J Clin Invest. 2018 Jan 2;128(1):359-368
pubmed: 29202483
Acta Neurol Scand Suppl. 2012;(193):iv-22
pubmed: 23106488
Gene Ther. 2015 Oct;22(10):767-80
pubmed: 25938190
Clin Genet. 1974;6(2):98-118
pubmed: 4430158
Nat Biotechnol. 2013 Sep;31(9):822-6
pubmed: 23792628
J Clin Invest. 2022 Jul 1;132(13):
pubmed: 35579942
Genome Res. 2001 Jun;11(6):1018-33
pubmed: 11381029
Curr Opin Neurol. 2015 Oct;28(5):462-7
pubmed: 26263471
Brain. 2001 Nov;124(Pt 11):2177-87
pubmed: 11673320
Sci Rep. 2017 Jul 10;7(1):4974
pubmed: 28694532
EMBO J. 1995 Mar 15;14(6):1122-8
pubmed: 7720703
Nat Genet. 2021 Jun;53(6):895-905
pubmed: 33846636
JAMA Neurol. 2013 Aug;70(8):981-7
pubmed: 23797954
Cell. 2013 Sep 12;154(6):1380-9
pubmed: 23992846
J Peripher Nerv Syst. 2023 Jun;28(2):150-168
pubmed: 36965137
Hum Mol Genet. 1996 May;5(5):563-9
pubmed: 8733121